Načítá se...
Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma
Seventy-five percent of lung adenocarcinomas with epidermal growth factor receptor (EGFR) mutations respond to treatment with the tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib; however, drug-resistant tumors eventually emerge. In 60% of cases, resistant tumors carry a secondary mutation...
Uloženo v:
| Hlavní autoři: | , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
The Company of Biologists Limited
2010
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2806903/ https://ncbi.nlm.nih.gov/pubmed/20007486 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1242/dmm.003681 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|